Latest News and Press Releases
Want to stay updated on the latest news?
-
Company announcement – No. 25 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (“Zealand...
-
Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches,...
-
Press release – No. 18 / 2025 Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases ...
-
Company announcement – No. 24 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
-
Press release – No. 17 / 2025 REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 Copenhagen, Denmark, December 1, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a...
-
Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025With petrelintide advancing at full speed and topline data rapidly approaching for...
-
Press release – No. 16 / 2025 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, November 12, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no....
-
Press Release – No. 15 / 2025 Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results Copenhagen, Denmark, November 6, 2025 – Zealand Pharma...
-
Company announcement – No. 22 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, October 17, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL)...
-
Company announcement – No. 21 / 2025 Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 Copenhagen, Denmark, September 30, 2025 – Zealand Pharma A/S ("the Company"...